Clinuvel PharmaceuticalsASX:CUV -1.54%86 EV-to-FCF is 7.31 as of Jul. 02, 2026, which is 76% below its 10-year median of 30.23. GuruFocus rates ASX:CUV with a GF Score™ of 86/100 and a GF Value™ of A$17.73 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 63.36% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Clinuvel Pharmaceuticals's Enterprise Value is A$292.78 Mil.
Clinuvel Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$40.08 Mil. Therefore, Clinuvel Pharmaceuticals's EV-to-FCF for today is 7.31.
The historical rank and industry rank for Clinuvel Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ASX:CUV'
s EV-to-FCF Range Over the Past 10 Years
Min: -78.36 Med: 30.23 Max: 161.23
Current: 6.76
During the past 13 years, the highest EV-to-FCF of Clinuvel Pharmaceuticals was 161.23. The lowest was -78.36. And the median was 30.23.
ASX:CUV's EV-to-FCF is ranked better than 63.36% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs ASX:CUV: 6.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clinuvel Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Clinuvel Pharmaceuticals's share price for today is A$10.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.644.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clinuvel Pharmaceuticals EV-to-FCF Related Terms
Clinuvel Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's EV-to-FCF falls into.
Clinuvel Pharmaceuticals's current Enterprise Value is A$292.78 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$40.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (ASX:CUV) has a EV-to-FCF of 7.31 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 76% below median its historical median of 30.23. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #122 out of 333 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Clinuvel Pharmaceuticals' EV-to-FCF too high?
Clinuvel Pharmaceuticals' current EV-to-FCF of 7.31 is 76% below median its 10-year median of 30.23. The Biotechnology industry median EV-to-FCF is 15.57. Clinuvel Pharmaceuticals' value of 7.31 is 53.1% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #122 out of 333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #122 out of 333 companies for EV-to-FCF. This puts Clinuvel Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 15.57. Clinuvel Pharmaceuticals' value of 7.31 is 53.1% below this benchmark. While the company's 10-year median is 30.23 vs. the industry median of 15.57, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current EV-to-FCF of 7.31 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current EV-to-FCF is 7.31, which is 76% below median its own 10-year median of 30.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.73, compared to a current price of A$10.26 — trading 42.1% below its estimated fair value. The current EV-to-FCF is 7.31, which is 76% below median its 10-year median of 30.23 and 53.1% below the Biotechnology industry median of 15.57. Clinuvel Pharmaceuticals' overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current EV-to-FCF is 7.31 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of A$10.26 is trading 42.1% below its estimated GF Value™ of A$17.73.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ASX:CUV:
EV-to-FCF: 7.31 (76% below median its 10-year median of 30.23)
GF Value™: A$17.73 vs. price of A$10.26 (42.1% below fair value)
Industry Position: 53.1% below the Biotechnology median (#122 of 333)
No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
86GF Score
Get the complete analysis for ASX:CUV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CUV has been successfully added to your 
